Retinitis Pigmentosa Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies

As per DelveInsight's assessment, globally, about 45+ key pharma and biotech companies are working on 45+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
" [https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Retinitis Pigmentosa Market.

The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

[https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The report provides insights into:

*
The report provides detailed insights into the emerging therapies for the treatment of Retinitis Pigmentosa and the aggregate therapies developed by major pharma companies.

*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Retinitis Pigmentosa market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Retinitis Pigmentosa - Emerging Therapies Mechanism of Action (MOA)

*
Gene transference

*
Cell replacements

*
Integrin inhibitors

*
Cell replacements; Nerve growth factor modulators

Retinitis Pigmentosa - Route of Administration

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as -

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

Molecule Type

Products have been categorized under various Molecule types, such as -

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Retinitis Pigmentosa Therapeutic Segment @ [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Retinitis Pigmentosa Therapeutics Landscape

Currently, there is no therapy that can stop the evolution of pigmentary retinopathies or restore vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery, etc. Gene therapy-based treatments are under research focus for the treatment of Retinitis pigmentosa.

There are approx. 45+ key companies developing therapies for Retinitis Pigmentosa. Currently, Biogen is leading the therapeutics domain with its Retinitis Pigmentosa drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Retinitis Pigmentosa Therapeutics Market Include:

*
Allegro Ophthalmics

*
Allergan

*
Biogen

*
Dompe Farmaceutici

*
Editas Medicine

*
Horama

*
ID Pharma

*
Ionis Pharmaceuticals

*
jCyte

*
MeiraGTx

*
Nacuity Pharmaceuticals

*
Neurotech

*
Nightstar Therapeutics/Biogen

*
Novartis Pharmaceuticals

*
OiDE OptoEye

*
ReNeuron

*
ReNeuron

*
Sanofi (Terminated)

*
SparingVision

And Many Others

Retinitis Pigmentosa Drugs Covered in the Report Include:

*
BIIB-112: Biogen

*
QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

*
ALG-1001: Allegro Ophthalmics/Hanmi Pharmaceuticals

*
NPI 001: Nacuity Pharmaceuticals

*
AAV8- RPGR/BIIB1121: Nightstar Therapeutics/Biogen

*
ReN 003: ReNeuron

*
jCell: jCyte

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Retinitis Pigmentosa Current Treatment Patterns

4. Retinitis Pigmentosa - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Retinitis Pigmentosa Late Stage Products (Phase-III)

7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)

8. Retinitis Pigmentosa Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinitis Pigmentosa Discontinued Products

13. Retinitis Pigmentosa Product Profiles

14. Key Companies in the Retinitis Pigmentosa Market

15. Key Products in the Retinitis Pigmentosa Therapeutics Segment

16. Dormant and Discontinued Products

17. Retinitis Pigmentosa Unmet Needs

18. Retinitis Pigmentosa Future Perspectives

19. Retinitis Pigmentosa Analyst Review

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report: [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.